Cytokinetics (CYTK) Short-term Investments (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Short-term Investments of $688.7 million for Q1 2026, down 20.34% year-over-year from $864.5 million in Q1 2025, and down 9.35% quarter-over-quarter from $759.7 million in Q4 2025.
Cytokinetics (CYTK) Short-term Investments (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Short-term Investments for 17 consecutive years, with $688.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments fell 20.34% year-over-year to $688.7 million; the TTM figure through Mar 2026 stood at $688.7 million (down 20.34% YoY), while the FY2025 annual figure was $759.7 million, down 22.57% from the prior year.
- Short-term Investments fell to $688.7 million in Q1 2026 per CYTK's latest filing, from $759.7 million in the prior quarter.
- Across five years, Short-term Investments topped out at $981.2 million in Q4 2024 and bottomed at $439.5 million in Q3 2023.
- Historically, Short-term Investments has averaged $682.9 million across 5 years, with a median of $717.0 million in 2022.
- Annual changes were most pronounced in 2023 — Short-term Investments slumped 42.27% — and 2024, when it surged 119.5%.
- Cytokinetics' Short-term Investments stood at $717.0 million in 2022, then slumped by 30.01% to $501.8 million in 2023, then surged by 95.53% to $981.2 million in 2024, then retreated by 22.57% to $759.7 million in 2025, then declined by 9.35% to $688.7 million in 2026.
- Business Quant data shows CYTK's Short-term Investments at $688.7 million in Q1 2026, $759.7 million in Q4 2025, and $737.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 910.42 Mn |
| Mar 31, 2026 | 688.71 Mn |
| Dec 31, 2025 | 759.70 Mn |
| Sep 30, 2025 | 737.07 Mn |
| Jun 30, 2025 | 783.20 Mn |
| Mar 31, 2025 | 864.54 Mn |
| Dec 31, 2024 | 981.16 Mn |
| Sep 30, 2024 | 964.80 Mn |
| Jun 30, 2024 | 866.63 Mn |
| Mar 31, 2024 | 498.99 Mn |
| Dec 31, 2023 | 501.80 Mn |
| Sep 30, 2023 | 439.55 Mn |
| Jun 30, 2023 | 497.08 Mn |
| Mar 31, 2023 | 562.35 Mn |
| Dec 31, 2022 | 717.00 Mn |
| Sep 30, 2022 | 761.43 Mn |
| Jun 30, 2022 | 492.40 Mn |
| Mar 31, 2022 | 493.55 Mn |
| Dec 31, 2021 | 358.97 Mn |
| Sep 30, 2021 | 387.07 Mn |